Program incorporates patient-driven study to inform research and drug development for KCNT1-related epilepsy SAN DIEGO and WASHINGTON, May 26, 2020 /PRNewswire/ — The KCNT1 Epilepsy Foundation, LunaPBC, and Genetic Alliance today announced a program to assemble a patient-led drug discovery community to study disease etiology and develop therapeutic interventions for patients with KCNT1-related epilepsy. The program is being launched in collaboration with Biogen, Inc. The […]Continue reading
There are currently more than 40 drugs approved to treat depression. For many patients, it can be an experience in trial and error to determine what drug or combination works the best with the fewest side effects. In an ideal situation, your genetic profile could inform your doctor the best drug, along with the best […]Continue reading
Take a look at any recent major news publication. Information about the latest scientific discovery or technological advancements can be found in nearly every issue. Yet for a disease that currently affects over 5 million Americans and is projected to affect almost 14 million by 2050, shockingly little progress has been made toward effective treatment, […]Continue reading
Interested in how LunaDNA can help power the research projects you're running? We’re ready when you are.
Interested in how LunaDNA can compliment the work you're already doing? Let us know how we can help.
© 2020 LunaDNA. LunaDNA and the moon logo are trademarks of LunaPBC, Inc. All other trademarks depicted herein are the property of their respective owners and there is no sponsorship, association, or affiliation between LunaPBC, Inc. and those trademark owners.</P